PMC Articles for MedGen (Select 1718245) - PMC

Select item 78699301.

SWI/SNF‐deficiency defines highly aggressive undifferentiated endometrial carcinoma

Basile Tessier‐Cloutier, Mackenzie Coatham, Mark Carey, Gregg S Nelson, Sarah Hamilton, Amy Lum, Robert A Soslow, Colin JR Stewart, Lynne M Postovit, Martin Köbel, Cheng‐Han Lee

J Pathol Clin Res. 2021 Mar; 7(2): 144–153. Published online 2020 Oct 30. doi: 10.1002/cjp2.188

PMCID:: PMC7869930

Article PDF–590K

Select item 68622962.

The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy

Mitsuhiro Nakamura, Takeshi Obata, Takiko Daikoku, Hiroshi Fujiwara

Int J Mol Sci. 2019 Nov; 20(21): 5482. Published online 2019 Nov 4. doi: 10.3390/ijms20215482

PMCID:: PMC6862296

Article PDF–2.0M

Select item 59474553.

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE‐Mutant Uterine Carcinosarcoma

Munveer S. Bhangoo, Peter Boasberg, Pareen Mehta, Julia A. Elvin, Siraj M. Ali, Winnie Wu, Samuel J. Klempner

Oncologist. 2018 May; 23(5): 518–523. Published online 2018 Jan 31. doi: 10.1634/theoncologist.2017-0342

PMCID:: PMC5947455

Article PDF–683K

Select item 51355884.

Regression of chemotherapy-resistant Polymerase ε (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab

Alessandro D. Santin, Stefania Bellone, Natalia Buza, Jungmin Choi, Peter E. Schwartz, Joseph Schlessinger, Richard P. Lifton

Clin Cancer Res. Author manuscript; available in PMC 2017 Jun 1.

Published in final edited form as: Clin Cancer Res. 2016 Dec 1; 22(23): 5682–5687. Published online 2016 Aug 2. doi: 10.1158/1078-0432.CCR-16-1031

PMCID:: PMC5135588

Article PDF–1.3M

Select item 38236465.

Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ Modulates Human Endometrial Cancer Cell Survival

J. J. Ma, D. Monsivais, M. T. Dyson, J. S. Coon, S. Malpani, M. Ono, H. Zhao, H. Xin, M. E. Pavone, J. J. Kim, D. Chakravarti, S. E. Bulun

Horm Cancer. 2013 Dec; 4(6): 358–370. Published online 2013 Aug 14. doi: 10.1007/s12672-013-0157-7

PMCID:: PMC3823646

Article PDF–847K

Select item 38225716.

Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin

Akihisa Suzuki, Akiko Horiuchi, Takashi Ashida, Tsutomu Miyamoto, Hiroyasu Kashima, Toshio Nikaido, Ikuo Konishi, Tanri Shiozawa

J Cell Mol Med. 2010 Sep; 14(9): 2305–2317. Published online 2009 Jul 6. doi: 10.1111/j.1582-4934.2009.00839.x

PMCID:: PMC3822571

Article PDF–1.2M

Select item 37125777.

Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib

Raya Faigenbaum, Roni Haklai, Gilad Ben-Baruch, Yoel Kloog

Oncotarget. 2013 Feb; 4(2): 316–328. Published online 2013 Feb 27. doi: 10.18632/oncotarget.867

PMCID:: PMC3712577

Article PDF–1.4M

Select item 32336488.

Trop-2 overexpression in poorly differentiated endometrial endometrioid adenocarcinoma: Implications for immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody

Eliana Bignotti, Antonella Ravaggi, Chiara Romani, Marcella Falchetti, Silvia Lonardi, Fabio Facchetti, Sergio Pecorelli, Joyce Varughese, Emiliano Cocco, Stefania Bellone, Peter E. Schwartz, Thomas J. Rutherford, Alessandro D. Santin

Int J Gynecol Cancer. Author manuscript; available in PMC 2012 Dec 1.

Published in final edited form as: Int J Gynecol Cancer. 2011 Dec; 21(9): 1613–1621. doi: 10.1097/IGC.0b013e318228f6da

PMCID:: PMC3233648

Article PDF–2.2M

Select item 28715959.

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

PM Pollock, MG Gartside, LC Dejeza, MA Powell, MA Mallon, Cancer Genome Project, H Davies, M Mohammadi, PA Futreal, MR Stratton, JM Trent, PJ Goodfellow

Oncogene. Author manuscript; available in PMC 2010 May 17.

Published in final edited form as: Oncogene. 2007 Nov 1; 26(50): 7158–7162. Published online 2007 May 21. doi: 10.1038/sj.onc.1210529

PMCID:: PMC2871595

Article PDF–92K

Select item 281375610.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

K El-Sahwi, S Bellone, E Cocco, M Cargnelutti, F Casagrande, M Bellone, M Abu-Khalaf, N Buza, F A Tavassoli, P Hui, D-A Silasi, M Azodi, P E Schwartz, T J Rutherford, S Pecorelli, A D Santin

Br J Cancer. 2010 Jan 5; 102(1): 134–143. Published online 2009 Nov 17. doi: 10.1038/sj.bjc.6605448

PMCID:: PMC2813756

Article PDF–646K

Select item 280648911.

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-specific Immunotherapy with Human Monoclonal Antibody Adecatumumab (MT201)

Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, Francesca Casagrande, Marta Bellone, Maysa Abu-Khalaf, Natalia Buza, Fattaneh A. Tavassoli, Pei Hui, Dominik Rüttinger, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Alessandro D. Santin

Mol Cancer Ther. Author manuscript; available in PMC 2010 Jul 6.

Published in final edited form as: Mol Cancer Ther. 2010 Jan; 9(1): 57–66. Published online 2010 Jan 6. doi: 10.1158/1535-7163.MCT-09-0675

PMCID:: PMC2806489

Article PDF–683K

Select item 239433512.

Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells

A Fedier, C Fowst, J Tursi, C Geroni, U Haller, S Marchini, D Fink

Br J Cancer. 2003 Oct 20; 89(8): 1559–1565. Published online 2003 Oct 14. doi: 10.1038/sj.bjc.6601316

PMCID:: PMC2394335

Article PDF–169K

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from MedGen

Items: 12

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity